• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Ann Rheum Dis. Dec 2005; 64(12): 1765–1768.
Published online Apr 20, 2005. doi:  10.1136/ard.2005.036459
PMCID: PMC1755302

Do steroids increase lymphoma risk? A case–control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis

Abstract

Background: Recent studies indicate increased risks of malignant lymphomas among individuals treated with corticosteroids, but have not taken into account the underlying reasons for steroid use, so the increased risks might be attributable to the underlying disease or concomitant treatments other than steroids. Polymyalgia rheumatica (PMR) and temporal arteritis (giant cell arteritis, GCA) are common inflammatory conditions treated with steroids as single immunosuppressive therapy, but data on lymphoma risk in GCA/PMR are limited.

Objective: To assess the risk of lymphoma associated with steroid treatment of GCA/PMR.

Methods: The association between GCA/PMR and malignant lymphomas (overall, and separately for non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphatic leukaemia) was examined in a nationwide, population based, case–control study of 42 676 lymphoma cases and 78 487 matched population controls, using prospectively recorded data on lymphomas from the Swedish cancer register 1964–2000 and data on pre-lymphoma hospital admissions for GCA/PMR from the Swedish inpatient register 1964–2000. Odds ratios (OR) associated with a pre-lymphoma hospital admission for GCA/PMR were calculated using conditional logistic regression.

Results: 153 lymphoma cases and 345 population controls had a history of GCA/PMR, resulting in an overall OR for malignant lymphomas of 0.81 (95% confidence interval, 0.67 to 0.98). The OR varied little with lymphoma type, sex, age, and calendar period. The OR for GCA was 0.67 (0.48 to 0.98) and for PMR, 0.83 (0.67 to 1.04).

Conclusions: Treated GCA is not associated with increased lymphoma risks, which suggests that even at considerable cumulative doses, steroids may not appreciably increase lymphoma risk.

Full Text

The Full Text of this article is available as a PDF (71K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Cartwright RA, McKinney PA, O'Brien C, Richards ID, Roberts B, Lauder I, Darwin CM, Bernard SM, Bird CC. Non-Hodgkin's lymphoma: case control epidemiological study in Yorkshire. Leuk Res. 1988;12(1):81–88. [PubMed]
  • Zhang Yawei, Holford Theodore R, Leaderer Brian, Zahm Shelia Hoar, Boyle Peter, Morton Lindsay McOmber, Zhang Bing, Zou Kaiyong, Flynn Stuart, Tallini Giovanni, et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control. 2004 May;15(4):419–428. [PubMed]
  • Kato Ikuko, Koenig Karen L, Shore Roy E, Baptiste Mark S, Lillquist Patricia P, Frizzera Glauco, Burke Jerome S, Watanabe Hiroko. Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin's lymphoma (NHL) (United States). Cancer Causes Control. 2002 Dec;13(10):965–974. [PubMed]
  • Holly Elizabeth A, Bracci Paige M. Population-based study of non-Hodgkin lymphoma, histology, and medical history among human immunodeficiency virus-negative participants in San Francisco. Am J Epidemiol. 2003 Aug 15;158(4):316–327. [PubMed]
  • Beiderbeck Annette B, Holly Elizabeth A, Sturkenboom Miriam C J M, Coebergh Jan W, Stricker Bruno H Ch, Leufkens Hubert G M. No increased risk of non-Hodgkin's lymphoma with steroids, estrogens and psychotropics (Netherlands). Cancer Causes Control. 2003 Sep;14(7):639–644. [PubMed]
  • Sørensen Henrik Toft, Mellemkjaer Lene, Nielsen Gunnar Lauge, Baron John A, Olsen Jørgen H, Karagas Margaret R. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst. 2004 May 5;96(9):709–711. [PubMed]
  • Ekström Karin, Hjalgrim Henrik, Brandt Lena, Baecklund Eva, Klareskog Lars, Ekbom Anders, Askling Johan. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum. 2003 Apr;48(4):963–970. [PubMed]
  • Björnådal Lena, Löfström Björn, Yin Li, Lundberg Ingrid E, Ekbom Anders. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol. 2002;31(2):66–71. [PubMed]
  • Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohmé I, Forsberg B, Eklund B, Fjeldborg O, Friedberg M, Frödin L, et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer. 1995 Jan 17;60(2):183–189. [PubMed]
  • Kamel OW, Weiss LM, van de Rijn M, Colby TV, Kingma DW, Jaffe ES. Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy. Am J Surg Pathol. 1996 Oct;20(10):1279–1287. [PubMed]
  • Baecklund E, Ekbom A, Sparén P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ. 1998 Jul 18;317(7152):180–181. [PMC free article] [PubMed]
  • Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med. 1985 Jan 21;78(1A):44–49. [PubMed]
  • Hazleman BL. The comparative incidence of malignant disease in rheumatoid arthritics exposed to different treatment regimens. Ann Rheum Dis. 1982;41 (Suppl 1):12–17. [PMC free article] [PubMed]
  • Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol. 1999 Aug;26(8):1705–1714. [PubMed]
  • Weyand Cornelia M, Goronzy Jörg J. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med. 2003 Sep 16;139(6):505–515. [PubMed]
  • Behn AR, Perera T, Myles AB. Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis. 1983 Aug;42(4):374–378. [PMC free article] [PubMed]
  • Nuenninghoff DM, Matteson EL. The role of disease-modifying antirheumatic drugs in the treatment of giant cell arteritis. Clin Exp Rheumatol. 2003 Nov-Dec;21(6 Suppl 32):S29–S34. [PubMed]
  • Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol. 1984;23(5):305–313. [PubMed]
  • Lunde AS, Lundeborg S, Lettenstrom GS, Thygesen L, Huebner J. The person-number systems of Sweden, Norway, Denmark, and Israel. Vital Health Stat 2. 1980;(84):1–59. [PubMed]
  • Myklebust Geirmund, Wilsgaard Tom, Jacobsen Bjarne Koster, Gran Jan Tore. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002 Oct;29(10):2143–2147. [PubMed]
  • Haga HJ, Eide GE, Brun J, Johansen A, Langmark F. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993 Aug;20(8):1335–1339. [PubMed]
  • Schaufelberger C, Bengtsson BA, Andersson R. Epidemiology and mortality in 220 patients with polymyalgia rheumatica. Br J Rheumatol. 1995 Mar;34(3):261–264. [PubMed]
  • Salvarani C, Macchioni PL, Tartoni PL, Rossi F, Baricchi R, Castri C, Chiaravalloti F, Portioli I. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol. 1987 Jul-Sep;5(3):205–215. [PubMed]
  • Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med. 1996 Feb;100(2):193–196. [PubMed]
  • Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med. 1982 Nov;97(5):672–680. [PubMed]
  • Herrick AL, McColl KE. Lack of certainty on the diagnosis of acute intermittent porphyria: comment on the concise communication by Cohen et al. Arthritis Rheum. 1998 Jan;41(1):188–189. [PubMed]
  • Cerhan James R, Anderson Kristin E, Janney Carol A, Vachon Celine M, Witzig Thomas E, Habermann Thomas M. Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer. 2003 Sep 20;106(5):784–788. [PubMed]
  • Knight Ann, Askling Johan, Ekbom Anders. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer. 2002 Jul 1;100(1):82–85. [PubMed]
  • Björnådal Lena, Baecklund Eva, Yin Li, Granath Fredrik, Klareskog Lars, Ekbom Anders. Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95. J Rheumatol. 2002 May;29(5):906–912. [PubMed]
  • Petursdottir V, Johansson H, Nordborg E, Nordborg C. The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations. Rheumatology (Oxford) 1999 Dec;38(12):1208–1212. [PubMed]
  • Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med. 1995 Aug 1;123(3):192–194. [PubMed]
  • Duhaut P, Bosshard S, Dumontet C. Giant cell arteritis and polymyalgia rheumatica: role of viral infections. Clin Exp Rheumatol. 2000 Jul-Aug;18(4 Suppl 20):S22–S23. [PubMed]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...